Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer

Cancer Research

Volumn 72, Issue 16, 2012, Pages 4074-4084

  Lenos, Kristiaan ^a   Grawenda, Anna M ^b   Lodder, Kirsten ^a   Kuijjer, Marieke L ^a   Teunisse, Amina F A S ^a   Repapi, Emmanouela ^b   Grochola, Lukasz F ^b   Bartel, Frank ^c   Hogendoorn, Pancras C W ^a   Wuerl, Peter ^d   Taubert, Helge ^e   Cleton Jansen, Anne Marie ^a   Bond, Gareth L ^b   Jochemsen, Aart G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d Department of General and Visceral Surgery   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN HDMX; PROTEIN INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADOLESCENT; ADULT; ALTERNATIVE SPLICING; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; OSTEOSARCOMA; PROGNOSIS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84865127671     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0215     Document Type: Article

References (42)

1. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002. p. 264-70.
2. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-28.
3. Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010;54:216-21.
4. Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van GM, Grimer RJ, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011;47:895-902.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
6. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137. (Pubitemid 29439303)
7. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011;223:116-26.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
9. Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas:MDM2amplification and p53 mutations found in progressive tumors. Pathol Res Pract 1998;194:615-21. (Pubitemid 28451457)
10. Park HR, Jung WW, Bertoni F, Bacchini P, Park JH, Kim YW, et al. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. Pathol Res Pract 2004;200:439-45. (Pubitemid 38937183)
11. Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2005;23:1483-90.
12. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 2003;23:4939-47. (Pubitemid 36793339)
13. Meulmeester E, Frenk R, Stad R, de GP, Marine JC, Vousden KH, et al. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 2003;23:4929-38. (Pubitemid 36793338)
14. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011;17:416-26.
15. Shvarts A, Steegenga WT, Riteco N, van LT, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996;15:5349-57. (Pubitemid 26336217)
16. Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 2005;331:750-60. (Pubitemid 40615506)
17. Riemenschneider MJ, Knobbe CB, Reifenberger G. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 2003;104:752-7. (Pubitemid 36418513)
18. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004;24:5835-43. (Pubitemid 38787968)
19. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001;61:1839-42. (Pubitemid 32691995)
20. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-6. (Pubitemid 44684754)
21. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 2011;17:494-504.
22. Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, Bache M, et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 2005;117:469-75. (Pubitemid 41429571)
23. Prodosmo A, Giglio S, Moretti S, Mancini F, Barbi F, Avenia N, et al. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) 2008;86:585-96.
24. Rallapalli R, Strachan G, Tuan RS, Hall DJ. Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells. J Cell Biochem 2003;89:563-75. (Pubitemid 36648778)
25. Lenos K, Jochemsen AG. Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011;2011:876173.
26. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011;17:2110-9.
27. Huvos AG. Bone tumors: diagnosis, treatment, and prognosis. Philadelphia, PA: W.B. Saunders company; 1991.
28. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010;49:40-51.
29. da Costa CE, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer 2009;48:239-49.
30. Cleton-Jansen AM, Anninga JK, Briaire-de BI, Romeo S, Oosting J, Egeler RM, et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009;101:1909-18.
31. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-5. (Pubitemid 43166006)
32. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat 2006;99:97-101. (Pubitemid 44168609)
33. Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG. Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene 2010;29:2415-26.
34. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14. (Pubitemid 23187639)
35. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8. (Pubitemid 38174664)
36. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65. (Pubitemid 46536647)
37. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
38. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
39. The TP53 Web Site [cited 2012 Mar 1]. Available from: http://p53.free.fr.
40. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011;91:1195-205.
41. Matijasevic Z, Steinman HA, Hoover K, Jones SN. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice. Mol Cell Biol 2008;28:1265-73. (Pubitemid 351214129)
42. Matijasevic Z, Krzywicka-Racka A, Sluder G, Jones SN. MdmX regulates transformation and chromosomal stability in p53-deficient cells. Cell Cycle 2008;7:2967-73.